Therapeutic angiogenesis in bioengineered muscle tissue

生物工程肌肉组织中的治疗性血管生成

• 批准号: 6953591
• 负责人: Shaun Michael Kunisaki
• 金额: $ 5.05万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6953591
• 关键词: angiogenesis; athymic mouse; biotechnology; blood circulation; human tissue; postdoctoral investigator; smooth muscle; tissue engineering; urinary bladder; vascular endothelial growth factors

DESCRIPTION (provided by applicant): Tissue engineering is an active area of investigation as an ultimate strategy for tissue and organ replacement. A major barrier to the ability to synthesize tissues for clinical use has been difficulties in vascularizing large volumes of engineered tissue. Preliminary data has shown that the induction of blood vessel growth within engineered skeletal muscle can be achieved using vascular endothelial growth factor (VEGF). This research training proposal seeks to further develop this model of angiogenesis induction using bladder smooth muscle tissue supplemented with VEGF. Human bladder smooth muscle will be seeded with collagen in the subcutaneous tissue of athymic mice with VEGF supplementation. The tissue will be retrieved at a later date, and the phenotypic and functional characteristics of engineered bladder muscle tissue will be investigated. This novel system of bioengineered smooth muscle would have applications in the treatment of incontinence and other disorders wherein there is a deficiency in functional smooth muscle tissue.

描述（由申请人提供）：组织工程是一个活跃的研究领域，是组织和器官替代的最终策略。合成用于临床应用的组织的能力的主要障碍是难以使大体积的工程化组织血管化。初步数据表明，血管内皮生长因子（VEGF）可以实现诱导血管生长的工程骨骼肌。这项研究培训计划旨在进一步开发这种使用膀胱平滑肌组织补充VEGF的血管生成诱导模型。人膀胱平滑肌将在补充VEGF的无胸腺小鼠的皮下组织中接种胶原蛋白。该组织将在稍后的日期检索，工程膀胱肌肉组织的表型和功能特性将进行研究。这种生物工程平滑肌的新系统将应用于治疗失禁和其中存在功能性平滑肌组织缺陷的其它病症。